Video

Dr. Kaplan: “There’s so much going on” in BPH

Author(s):

Urology Times staff
Conference|LUGPA Annual Meeting

“I'm basically highlighting some of the data that's currently out there, but more importantly, some of the data that [are] just emerging,” says Steven A. Kaplan, MD.

In this video, Steven A. Kaplan, MD, shares talking points from his presentation at the 2021 LUGPA annual meeting. Kaplan is a professor of urology at the Icahn School of Medicine and director of the Men’s Wellness Program at Mount Sinai, New York, New York.

Related Videos
Related Content
Welcome to Fabulous Las Vegas Neon Sign | Image Credit: © somchaij - stock.adobe.com
April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke
We preview several noteworthy P2 presentations in the urologic oncology space.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor
“Among active surveillance patients, 82% are metastases-free, and 60% were metastases-free and had an intact, unradiated bladder,” said Pooja Ghatalia, MD.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com
February 17th 2025

Casdatifan is linked with promising safety, efficacy in clear cell RCC

Benjamin P. Saylor
“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.
Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com
February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor
"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.
© 2025 MJH Life Sciences

All rights reserved.